With the advent of the Coronavirus Pandemic, coupled with the disassociation of several counties' trade relations towards China, the time has never been so ripe for the Indian medical manufacturing industry, be it in terms of the production of APIs, Intermediates, or other Specialty chemicals. The entire world is looking towards India. The country has the potential to be the leader in the world pertaining to Active Pharmaceutical Ingredient (API), Specialty chemical, and other Intermediate chemical production.
DK Pharmachem is one of the biggest players in the API, Specialty Chemical, and Intermediate production domain in India. Having initially established as an intermediate and specialty manufacturer in the 1980s - D.K Pharmachem ultimately reached to the APIs in 2005. At present, the visionary entrepreneur Mr. Rakesh Bakshi led production company is one of the biggest suppliers of in-demand API, Specialty Chemical, and Intermediate products across the globe, catering to major companies that include the likes of (Sanofi) (Tewa) among many others.
DK Pharmachem holds the distinction of being the only supplier of certain specific APIs and key Intermediates across the globe. The company has built up strong relationships with its customers, and also holds the distinction of being the only reliable supplier for companies for the last 15 years and more. For instance, DK Pharmachem has been supplying an Israel based company with a key Intermediate raw material for the past 22 years. Mr. Rakesh Bakshi and his team are the biggest manufacturers of that key raw material and the only supplier for the Israel based company.
Over the years, the quantity of production orders has increased without compromising on the quality. Mr. Rakesh Bakshi and his close-knit team have disrupted the market by offering certain APIs at rates as low as 200 Euros, which otherwise would cost more than 300 Euros.
Traditionally, China had always been a key manufacturer of Intermediates and Specialty Chemicals. DK Pharmachem's 40 years of expertise in terms of the manufacturing of Intermediates has allowed them to hold mastery over the process, which has made them independent from China's dependency.
Improvisation in the Process is the Key
For the key Intermediates, there is an entire chain of reactions and integrations that the Pharmachem team has covered over the years. The company's in-house R&D unit is recognized by DSIR, Government of India. The company has developed methods to manufacture or improvise the products in-house.
The R & D team, led by Mr. Karan Bakshi and Dr. Palkar, constantly improvises on the processes and products. There are also a few products the team has developed in-house.
The Pharmachem team is once again coming up with a new technology in the Bio-tech segment. The team is on course of making key raw material for the insulin. DK Pharmachem would be the first to manufacture it synthetically. The company would be the first manufacturer of the product named as Tripchill, which might be in line for production by the end of September 2020.
DK Pharmachem holds the distinction of being the only supplier of certain specific APIs and key Intermediates across the globe
Recently, the Pharmachem team has been heavily involved in Synthetic products. There are certain specific advantages that Synthetic based pharma products have over an animal or plant-based products. As it is evident from the recent Coronavirus Pandemic, animal and plant-based products might risk passing on diseases if not handled with utmost care. DK Pharmachem is looking forward to capitalizing on this opportunity prevailing in the market.
The API industry had always been there for a long time; now, Mr. Rakesh Bakshi sees the recent advent of Bio-tech to forward further expansions in the upcoming future. In recent times, the focus of the government and the clients alike have shifted, and when there is a demand there will always be an upward trend for APIs in the segment of Pharma according to Mr. Bakshi. The recent developments in Bio-tech are immensely positive. The developments are coming here itself, and the Pharmachem team is working on these new technologies such as Bio-reactors, Bio-loop reactors, and many more.
A well-Integrated Company
ISO 9001 certified – DK Pharmachem has a dedicated API facility with WHO GMP certification & PMDA approval. The company's facility is also accredited and certified by the Japanese FDA. In addition to the top-notch facilities, DK Pharmachem also holds the distinction of developing Vitamin D3 derivatives indigenously at their GMP plant. The company was the first to establish 2 APIs in India and is one of the largest producers of PTS Acid, PTS Amide & Chloramine T in India.
The Founder, Mr. Rakesh Bakshi, considers his dedicated team as his greatest strength. More than 25% percent of the employees have been working for DK Pharmachem for more than 20 years. Besides, DK Pharmachem has strong commitments towards Corporate Social Responsibility (CSR) activities that focus on education, health, and sports. DK Pharmachem has an active football team playing in the Senior Bombay Football Division League.
Mr. Rakesh Bakshi, Founder A Visionary Entrepreneur
A graduate from the University of Bombay, Mr. Rakesh Bakshi belongs to the bracket of one of he pioneers in the Indian Intermediate and Specialty Chemical manufacturing sector. Since the decade of the 1980s onwards the visionary entrepreneur has transformed his closeknit company comprising of family members - DK Pharmachem into one of the largest suppliers of key Intermediates, Specialty Chemicals and APIs across the globe.